Business Description
Aptevo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03835L1089
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.61 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.09 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 33 | |||||
3-Year EPS without NRI Growth Rate | 35.2 | |||||
3-Year FCF Growth Rate | 52 | |||||
3-Year Book Growth Rate | -44.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 66.53 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 42.97 | |||||
12-1 Month Momentum % | -26.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.7 | |||||
Quick Ratio | 1.7 | |||||
Cash Ratio | 1.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -64 | |||||
Shareholder Yield % | -114.25 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -282.9 | |||||
ROA % | -119 | |||||
ROIC % | -303.78 | |||||
ROC (Joel Greenblatt) % | -442.36 | |||||
ROCE % | -180.89 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.33 | |||||
Price-to-Tangible-Book | 1.33 | |||||
EV-to-EBIT | -0.14 | |||||
EV-to-EBITDA | -0.14 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | -0.15 | |||||
Earnings Yield (Greenblatt) % | -714.29 | |||||
FCF Yield % | -364.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Aptevo Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -90.083 | ||
Beta | 0.74 | ||
Volatility % | 39.44 | ||
14-Day RSI | 42.97 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 4.953 | ||
12-1 Month Momentum % | -26.81 | ||
52-Week Range (€) | 0.0191 - 7.48 | ||
Shares Outstanding (Mil) | 18.51 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aptevo Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aptevo Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Aptevo Therapeutics Inc Frequently Asked Questions
What is Aptevo Therapeutics Inc(FRA:AP8)'s stock price today?
When is next earnings date of Aptevo Therapeutics Inc(FRA:AP8)?
Does Aptevo Therapeutics Inc(FRA:AP8) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |